The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
GlaxoSmithKline plc’s BCMA-directed antibody-drug conjugate belantamab mafodotin has received a unanimous vote in favor of approval from a US Food and Drug Administration advisory committee as a treatment for relapsed or refractory multiple myeloma.
This was despite trial data showing it can cause a serious eye problem, keratopathy, in patients, with a pre-meeting review by the FDA flagging concerns about its overall benefit/safety profile
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
